2023/08/02 ALA-3000 has received an Intention to Grant (IGRA) from European Patent Office (EPO) after examination. (Patent Application No. 20739053.5)Post author:alarpharmPost published:10 . 8 . 2023Post category:Media releases You Might Also Like 2023/07/25 ALA-3000 Received the patent, KETAMINE PAMOATE AND USE THEREOF from China National Intellectual Property Administration (CNIPA) , NO : 202080007207.5 26 . 7 . 2023 2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021 2021/04/16 ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office (Application No. 10-2019-7009185). 21 . 4 . 2021 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021 2021/04/12 ALA-1000 Receive Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) (Application No. 2019102895). 21 . 4 . 2021
2023/07/25 ALA-3000 Received the patent, KETAMINE PAMOATE AND USE THEREOF from China National Intellectual Property Administration (CNIPA) , NO : 202080007207.5 26 . 7 . 2023
2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021
2021/04/16 ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office (Application No. 10-2019-7009185). 21 . 4 . 2021
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021
2021/04/12 ALA-1000 Receive Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) (Application No. 2019102895). 21 . 4 . 2021